Facebook-f Tiktok Instagram Youtube Whatsapp Linkedin
Facebook-f Tiktok Instagram Youtube Whatsapp Linkedin

Doctor Profile

Back

Dr. Yingbin Liu

HPB Surgery

Professor · Chief Physician · Doctoral Supervisor · MD

Dr. Liu is chief physician and administrative director of Hepatopancreatobiliary Surgery and General Surgery, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, director of Shanghai Institute of Oncology, director of Shanghai Institute of Biliary Tract Diseases, deputy director of the State Key Laboratory of Oncogenes and Related Genes，member of the Liver Surgery Group, Surgery Branch of the Chinese Medical Association, standing committee member of the Surgery Branch, Chinese Medical Doctor Association, deputy director of the Surgery Branch, Shanghai Medical Association, president-elect of the Biliary Tract Tumor Committee, Chinese Anti-Cancer Association, deputy director of the Pancreatic Disease Committee, Chinese Research Hospital Association.

HPB Surgery Expert

Gallbladder Cancer

Pancreatic Head Cancer

Liver Cancer

40+ yrs

Experience

7000+

Surgeries

70+

SCI Papers

Expertise

Dr. Liu specializes in both clinical and basic research in hepatopancreatobiliary surgery, with particular expertise in the standardized surgical resection and multidisciplinary treatment of gallbladder cancer, intrahepatic cholangiocarcinoma, hilar cholangiocarcinoma, and pancreatic cancer.

He pioneered the innovative “bundled pancreaticojejunostomy” technique and was the first in China to propose the concept of total mesopancreas excision for pancreatic head cancer.

Internationally, Dr. Liu was the first to systematically identify the somatic mutation landscape and key tumor-driving genes and signaling pathways (notably the ErbB signaling pathway) associated with gallbladder cancer. He also established the world’s first lymphatic metastasis model for gallbladder cancer and successfully developed the GBC-SD/HL cell line, characterized by high lymphatic metastatic potential.

Professional Background

Dr. Liu has devoted more than 40 years to clinical practice and academic teaching, preforming over 7000 surgeries, with a focus on hepatopancreatobiliary surgery, which includes:

  1. Molecular biological mechanisms of gallbladder cancer initiation and progression

  2. Early diagnosis of gallbladder cancer

  3. Comprehensive treatment of gallbladder cancer

  4. Application of translational medicine in gallbladder cancer

As principal investigator, he has led multiple national multicenter clinical studies, advancing precision medicine in gallbladder cancer and promoting the clinical application of targeted therapies. He also established the largest multicenter single-disease database for gallbladder cancer in China, providing critical guidance for the standardized diagnosis and treatment of this disease.

Awards & Honors

  • Awarded “Shanghai Craftsman”

  • Named Shanghai Science and Technology Elite

  • Selected as a National Outstanding Young and Middle-aged Expert in Health and Family Planning

  • Elected Foreign Member of the American College of Surgeons

  • Included in the National “Hundred, Thousand, Ten Thousand Talents Project” and honored as an “Outstanding Young and Middle-aged Expert with Distinguished Contributions”

  • Recipient of the National May 1st Labor Medal

  • Distinguished Professor of the Changjiang Scholars Program

  • Recognized as Shanghai Outstanding Academic Leader and Shanghai Leading Talent

  • First Prize, Zhejiang Provincial Science and Technology Progress Award

  • Second Prize, National Science and Technology Progress Award

  • First Prize, China Higher Education Science and Technology Progress Award

  • First Prize, Huaxia Medical Science and Technology Award

  • First Prize, Ministry of Education Science and Technology Progress Award

  • First Prize, Ministry of Education Natural Science Award

  • Second Prize, Chinese Medical Science and Technology Award

  • Recipient, 19th Wu Jieping–Paul Janssen Medical and Pharmaceutical Award

  • First Prize, Shanghai Natural Science Award

Recent Key Publications:

  1. Fatao Liu, Yongsheng Li, Dongjian Ying, Shimei Qiu, Yong He, Maolan Li, Yun Liu, Yijian Zhang, Qin Zhu, Yunping Hu, Liguo Liu, Guoqiang Li, Weihua Pan, Wei Jin, Jiasheng Mu, Yang Cao & Yingbin Liu. Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder. Signal Transduction and Targeted Therapy, 2021, 6(1): 55. (IF=13.496)
  2. Xiaoling Song, Xu’an Wang, Yunping Hu, Huaifeng Li, Tai Ren, Yongsheng Li, Liguo Liu, Lin Li, Xuechuan Li, Ziyi Wang, Wen Huang, Runfa Bao, Yijian Zhang, Maolan Li, Xuefeng Wang, Feng Liu, Jun Gu, Linhui Zheng, Wenguang Wu, Yingbin Liu. A metagenomic study of biliary microbiome change along the cholecystitis-carcinoma sequence. Clin Transl Med, 2020, 10(2): e97. (IF= 7.919)
  3. Maolan Li, Fatao Liu, Fei Zhang, Weiping Zhou, Xiaoqing Jiang, Yuan Yang, Kai Qu, Yueqi Wang, Qiang Ma, Ting Wang, Lu Bai, Zheng Wang, Xiaoling Song, Yidi Zhu, Ruiyan Yuan, Yuan Gao, Yongchen Liu, Yunpeng Jin, Huaifeng Li, Shanshan Xiang, Yuanyuan Ye, Yijian Zhang, Lin Jiang, Yunping Hu, Yajuan Hao, Wei Lu, Shili Chen, Jun Gu, Jian Zhou, Wei Gong, Yong Zhang, Xuefeng Wang, Xiyong Liu, Chang Liu, Houbao Liu, Yun Liu, Yingbin Liu. Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis. Gut, 2019, 68(6): 1024-33. (IF=17.943)
  4. YunPing Hu, YunPeng Jin, XiangSong Wu, Yang Yang, YongSheng Li, HuaiFeng Li, ShanShan Xiang, XiaoLing Song, Lin Jiang, YiJian Zhang, Wen Huang, ShiLi Chen, FaTao Liu, Chen Chen, Qin Zhu, HongZhuan Chen, Rong Shao, Ying-Bin Liu. LncRNA-HGBC stabilized by HuR promotes gallbladder cancer progression by regulating miR-502-3p/SET/AKT axis. Molecular Cancer, 2019, 18(1): 167. (IF=10.679)
  5. Maolan Li, Zhou Zhang, Xiaoguang Li, Junyi Ye, Xiangsong Wu, Zhujun Tan, Chang Liu, Baiyong Shen, Xu’an Wang, Wenguang Wu, Daizhan Zhou, Di Zhang, Ting Wang, Bingya Liu, Kai Qu, Qichen Ding, Hao Weng, Qian Ding, Jiasheng Mu, Yijun Shu, Runfa Bao, Yang Cao, Peizhan Chen, Tianyu Liu, Lin Jiang, Yunping Hu, Ping Dong,
  6. Ren T , Li Y , Zhang X ,et al.Protocol for a gallbladder cancer registry study in China: the Chinese Research Group of Gallbladder Cancer (CRGGC) study[J].BMJ Open, 2021, 11(2):e038634.DOI:10.1136/bmjopen-2020-038634.
  7. Liu F , Li Y , Ying D ,et al.Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder[J].Signal Transduction and Targeted Therapy, 2021, 6(1).DOI:10.1038/s41392-020-00412-3.
  8. Zhang Y , Zuo C , Liu L ,et al.Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancer[J].Journal of Hepatology, 2021.DOI:10.1016/j.jhep.2021.06.023.
  9. Song X , Li M , Wu W ,et al.Regulation of BMP2K in AP2M1-mediated EGFR internalization during the development of gallbladder cancer[J].Signal Transduction and Targeted Therapy[2025-06-11].DOI:10.1038/s41392-020-00250-3.
  10. Yin Z , Chen T , Shu Y ,et al.A Gallbladder Cancer Survival Prediction Model Based on Multimodal Fusion Analysis[J].Digestive Diseases and Sciences, 2022:1-15.DOI:10.1007/s10620-022-07782-4.
  11. Zhao Y , Yang M , Wang S G ,et al.An Overview of Epigenetic Methylation in Pancreatic Cancer Progression[J].Frontiers in Oncology, 2022, 12.DOI:10.3389/fonc.2022.854773.
  12. Tan Z , Li M , Wu W ,et al.NLK is a key regulator of proliferation and migration in gallbladder carcinoma cells (vol 369, pg 27, 2012)[J].Molecular and Cellular Biochemistry: An International Journal for Chemical Biology, 2021(12):476.
  13. Yuan R , Li Y , Yang B ,et al.LOXL1 exerts oncogenesis and stimulates angiogenesis through the LOXL1-FBLN5/αvβ3 integrin/FAK-MAPK axis in intrahepatic cholangiocarcinoma[J].Molecular Therapy – Nucleic Acids, 2021, 23.DOI:10.1016/j.omtn.2021.01.001.
  14. Cui X , Li X , Cui J ,et al.Modified FOLFIRINOX for unresectable locally advanced or metastatic gallbladder cancer, a comparison with GEMOX regimen.[J].Hepatobiliary surgery and nutrition, 2021, 10(4):498-506.DOI:10.21037/hbsn-20-846.
  15. Liu Y , Liang H , Wang J ,et al.Digital Surgical Diagnosis and Treatment of Gallbladder Cancer[J]. 2021.DOI:10.1007/978-981-33-6769-2_15.
  16. Ren T , Li Y S , Dang X Y ,et al.Prognostic significance of regional lymphadenectomy in T1b gallbladder cancer:Results from 24 hospitals in China[J].World Journal of Gastrointestinal Surgery, 2021.DOI:10.4240/wjgs.v13.i2.176.
  17. Li Y , Yuan R , Ren T ,et al.Role of Sciellin in gallbladder cancer proliferation and formation of neutrophil extracellular traps[J].Cell Death & Disease[2025-06-11].DOI:10.1038/s41419-020-03286-z.
  18. Wang X A , Wang J W , Li J T ,et al.Binding Pancreaticojejunostomy[J]. 2020.DOI:10.1007/978-981-32-9864-4_29.
  19. Wang X A , Liu Y B , Peng S Y .Binding Pancreaticogastrostomy[M]. 2020.
  20. Zhang Y , Du P , Li Y ,et al.TASP1 Promotes Gallbladder Cancer Cell Proliferation and Metastasis by Up-regulating FAM49B via PI3K/AKT Pathway[J].International Journal of Biological Sciences, 2020, 16(5):739-751.DOI:10.7150/ijbs.40516.
Book Appointment

Contact Us

We would love to speak with you.
Feel free to reach out using the below details.

Find us Here

  • +1 8324667523
  • services@chinahealthtrip.com

Fill out the form below!

Doctor Profile

Dr. Xiuying Xiao

Gastrointestinal Oncology

Chief Physician · Master’s Supervisor · MD

Clinical Oncology

Gastric Cancer

Intestinal Cancer

NENs

Experience

0 +yrs
0 +

Multi-center Clinical Trials

0 +

SCI Papers

Second Opinion ＄399

Contact Me

Expertise

Dr. Xiao specializes in comprehensive treatment—including chemotherapy, targeted therapy, and immunotherapy—for digestive tract and neuroendocrine tumors, as well as personalized and precise management of complex and challenging malignancies. Her research involves the basic mechanisms and translational studies of gastrointestinal tumors, including biomarker identification and resistance mechanisms, aiming to accelerate the clinical application of scientific findings.

Professional Background

Dr. Xiao has worked in the field of oncology for over 20 years, gaining extensive clinical experience in the diagnosis and treatment of gastrointestinal and neuroendocrine tumors. As a principal investigator (PI) or co-PI, she has participated in numerous domestic and international multicenter clinical trials of novel therapies, with a research focus on mechanisms of drug resistance in metastatic disease and overcoming resistance to targeted therapies. She also contributed to the compilation of oncology-related works such as Cancer Patient Rehabilitation Guidance, General Clinical Oncology, and Gastric Cancer: Translational Research from Basic to Clinical.

Awards & Honors

Honored with the Hurun·PingAn Good Doctors of China 2017

Recognized as a Model Physician at the 4th Yangtze River Delta Benevolent Doctor Awards

Recognized as Young Outstanding Worker of Xuhui District

Professional Background

  1. Lin X, Han T, Zhuo M, Liu T, Liu Z, Xiang D, Li H, Xiao X. A retrospective study of clinicopathological characteristics and prognostic factors of Krukenberg tumor with gastric origin. J Gastrointest Oncol. 2022 Jun;13(3):1022-1034. doi: 10.21037/jgo-22-464. PMID: 35837152; PMCID: PMC9274061.
  2. Lin X L , Xiao X Y , Oncology D O ,et al.Progress in neoadjuvant drug therapy of rectal cancer[J].World Chinese Journal of Digestology, 2018, 26(22):1340-1347.DOI:10.11569/wcjd.v26.i22.1340.
  3. Lin X L , Xu Q , Tang L ,et al.Regorafenib inhibited gastric cancer cells growth and invasion via CXCR4 activated Wnt pathway[J].Plos One, 2017, 12(5).DOI:10.1371/journal.pone.0177335.
  4. Lin J R , Zhang Q , Cai Y ,et al.S5 Table[J]. 2017.
  5. Wang L , Shen X , Wang Z ,et al.A molecular signature for the prediction of recurrence in colorectal cancer[J].Molecular Cancer, 2015, 14(1):22.DOI:10.1186/s12943-015-0296-2.
  6. Ren F , Wang L , Shen X ,et al.MYBL2 is an independent prognostic marker that has tumor-promoting functions in colorectal cancer[J].American Journal of Cancer Research, 2015.
  7. Chi Y , Wang L , Xiao X ,et al.Abnormal expression of CDK11.sup.p58.sup. in prostate cancer[J]. 2014.DOI:10.1186/1475-2867-14-2.
  8. Yayun,Chi,Lisha.Abnormal expression of CDK11p58 in prostate cancer[J].Cancer Cell International, 2014, 14(1):2-2.DOI:10.1186/1475-2867-14-2.
  9. Yayun,Chi,Lisha,et al.Abnormal expression of CDK11p58 in prostate cancer[J].Cancer Cell International, 2014.DOI:10.1186/1475-2867-14-2.
  10. Cuenca-López, María D, Montero J C , Morales J C ,et al.Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling[J].BMC Cancer,14,1(2014-04-30), 2014, 14(1):302.DOI:10.1186/1471-2407-14-302.
  11. Wang Q , Huang Z , Guo W ,et al.MicroRNA-202-3p Inhibits Cell Proliferation by Targeting ADP-Ribosylation Factor-like 5A in Human Colorectal Carcinoma[J].Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2014, 20(5):1146-57.DOI:10.1158/1078-0432.CCR-13-1023.
  12. Xiao X , Wang L , Wei P ,et al.Role of MUC20 overexpression as a predictor of recurrence and poor outcome in colorectal cancer.[J].Journal of Translational Medicine, 2013.DOI:10.1186/1479-5876-11-151.
  13. Xiao X , Wang L , Wei P ,et al.Role of MUC20 overexpression as a predictor of recurrence and poor outcome in colorectal cancer[J].Journal of Translational Medicine, 2013, 11(1):151-151.DOI:10.1186/1479-5876-11-151.
  14. [13] Brusi D ,Carles Roqué, Maspla J .Fundamentos conceptuales y didácticos: Los procesos geológicos externos: las infinitas interacciones en la superficie de la Tierra[J].Plos One, 2013, 7(9):168-168.DOI:10.1371/journal.pone.0044548.
  15. [14] Wang Q , Huang Z , Ni S ,et al.Plasma miR-601 and miR-760 Are Novel Biomarkers for the Early Detection of Colorectal Cancer[J].PLoS ONE, 2012, 7(9):e44398-.DOI:10.1371/journal.pone.0044398.
  16. [15] Qifeng Wang,Zhaohui Huang,Shujuan Ni,et al.Plasma miR-601 and miR-760 Are Novel Biomarkers for the Early Detection of Colorectal Cancer.[J].PLoS ONE, 2012.DOI:10.1371/journal.pone.0044398.
  17. [16] Wang L , Xiao X , Li D ,et al.Abnormal expression of GADD45B in human colorectal carcinoma[J].Journal of Translational Medicine, 2012, 10(1):215-215.DOI:10.1186/1479-5876-10-215.
  18. [17] Wang Q , Huang Z , Ni S ,et al.TORTS-LIABILITY OF CHARITABLE HOSPITAL FOR INJURIES TO PATIENT CAUSED BY NEGLIGENCE OF NURSE AND INTERN. [New York][J].Plos One, 2012, 7(9):168-168.DOI:10.1371/journal.pone.0044398.
  19. [18] Zhu Y F , Ke H L , Guo X Z ,et al.PI3K expression and PIK3CA mutations are related to colorectal cancer metastases[J].World Journal of Gastroenterology, 2012.DOI:CNKI:SUN:ZXXY.0.2012-28-015.
  20. [19] Lisha,Wang,Xiuying,et al.Abnormal expression of GADD45B in human colorectal carcinoma[J].Journal of Translational Medicine, 2012.DOI:10.1186/1479-5876-10-215.
  21. [20] Hui L , Xiao-Min Y , Jia-Xin W ,et al.The VNTR Polymorphism of the DC-SIGNR Gene and Susceptibility to HIV-1 Infection: A Meta-Analysis[J].Plos One, 2012, 7(9):168-168.DOI:10.1371/journal.pone.0042972.

Contact Us

We would love to speak with you.
Feel free to reach out using the below details.

Find us Here

  • +1 8324667523
  • services@chinahealthtrip.com

Fill out the form below!

WhatsApp

Book Your Appointment